News & Events about Repare Therapeutics Inc.
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small...
Globe Newswire
3 months ago
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (Repare or the Company) (NASDAQ: RPTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX PR Newswire NEW YORK, Feb. 13, 2023 NEW YORK, Feb. 13, 2023...
Business Wire
3 months ago
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (Repare or the Company) (NASDAQ: RPTX). Investors who purchased Repare securities are encouraged to obtain additional information and assist the...
Morgan Stanley cut shares of Repare Therapeutics (NASDAQ:RPTX Get Rating) from an overweight rating to an equal weight rating in a report released on Friday, MarketBeat reports. The firm currently has $15.00 price objective on the stock, down from their previous price objective of $28.00. A number ...